-
1 Comment
CStone Pharmaceuticals is currently in a long term uptrend where the price is trading 42.3% above its 200 day moving average.
From a valuation standpoint, the stock is 92.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Its net income has increased by 48.7% to $-550M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.6% to $-330M since the same quarter in the previous year.
Based on the above factors, CStone Pharmaceuticals gets an overall score of 4/5.
| ISIN | KYG2588M1006 |
|---|---|
| Exchange | HK |
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 4.7058 |
|---|---|
| Market Cap | 4B |
| PE Ratio | None |
| Beta | 0.12 |
| Dividend Yield | None |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2616.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
